Recent News

Two projects from a portfolio of 57 that the Tri-I TDI has supported have “graduated” with the demonstration that the compounds under study work in preclinical contexts. These compounds are now ready for the next phase of therapeutic development – a phase intended to lead to investigational new drugs. A third project, which originated at Weill Cornell Medicine, is expected to move forward later this month. These projects are candidates for advancement into Bridge Medicines, Inc., a for-profit company established in 2016 by the three Tri-I TDI academic founders, Takeda, and two investment firms – Bay City Capital and Deerfield Management – designed to take Tri-I TDI projects into readiness for clinical trials over a two- to three-year time frame.

The atomic structure of an elusive type of membrane protein has finally been solved by scientists at the Sloan Kettering Institute.

Researchers have discovered that cancer cells may hijack an immune response to spread from a primary tumor to distant organs.

Scientists have uncovered a molecule that, in mice, can promote the regeneration of the thymus, where T cells develop.

Science could lead to a new type of opioid drug that blocks pain but has a lower potential for addiction or abuse.

When this feathered patient found her way into a New York laboratory in 1909, she changed the course of cancer science.

As 2017 draws to a close, take a look back at the scientific discoveries that deepened our understanding of cancer in the past year.

MSK investigators are learning how cancer cells escape from the original tumor and hide out in the body. Their goal is to prevent metastatic tumors from forming.

A team led by MSK molecular biologist Scott Lowe is making progress against fibrolamellar hepatocellular carcinoma.

Researchers have discovered how a high level of the protein PSMA in cells helps fuel prostate cancer.